1.Morley, JE, Thomas, DR & Wilson, MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83, 735–743.
2.Tisdale, MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2, 862–871.
3.Tisdale, MJ (2005) Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 20, 340–348.
4.Slaviero, KA, Read, JA, Clarke, SJ et al. (2003) Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 46, 148–157.
5.Fearon, KC, Voss, AC & Hustead, DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83, 1345–1350.
6.Deans, DA, Wigmore, SJ, de Beaux, AC et al. (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 94, 1501–1508.
7.Skipworth, RJ, Stewart, GD, Dejong, CH et al. (2007) Pathophysiology of cancer cachexia: Much more than host-tumour interaction? Clin Nutr 26, 667–676.
8.Argiles, JM, Busquets, S & Lopez-Soriano, FJ (2006) Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 130, 199–217.
9.Spiegelman, BM & Flier, JS (2001) Obesity and the regulation of energy balance. Cell 104, 531–543.
10.Bluher, M (2005) Transgenic animal models for the study of adipose tissue biology. Best Pract Res Clin Endocrinol Metab 19, 605–623.
11.Rosen, ED & Spiegelman, BM (2006) Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847–853.
12.Trayhurn, P & Wood, IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92, 347–355.
13.Mohamed-Ali, V, Pinkney, JH & Coppack, SW (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22, 1145–1158.
14.Ahima, RS & Flier, JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11, 327–332.
15.Fruhbeck, G, Gomez-Ambrosi, J, Muruzabal, FJ et al. (2001) The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280, E827–E847.
16.Rajala, MW & Scherer, PE (2003) Minireview: The adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765–3773.
17.Trayhurn, P & Bing, C (2006) Appetite and energy balance signals from adipocytes. Philos Trans R Soc Lond B Biol Sci 361, 1237–1249.
18.Ogiwara, H, Takahashi, S, Kato, Y et al. (1994) Diminished visceral adipose tissue in cancer cachexia. J Surg Oncol 57, 129–133.
19.Fouladiun, M, Korner, U, Bosaeus, I et al. (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care – correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103, 2189–2198.
20.Lieffers, JR, Mourtzakis, M, Hall, KD et al. (2009) A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 89, 1173–1179.
21.Fearon, KC & Preston, T (1990) Body composition in cancer cachexia. Infusionstherapie 17, Suppl. 3, 63–66.
22.Fearon, KC (1992) The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51, 251–265.
23.Kalantar-Zadeh, K, Horwich, TB, Oreopoulos, A et al. (2007) Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 10, 433–442.
24.Halabi, S, Ou, SS, Vogelzang, NJ et al. (2007) Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 110, 1478–1484.
25.Ishiko, O, Nishimura, S, Yasui, T et al. (1999) Metabolic and morphologic characteristics of adipose tissue associated with the growth of malignant tumors. Jpn J Cancer Res 90, 655–659.
26.Bing, C, Russell, S, Becket, E et al. (2006) Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer 95, 1028–1037.
27.Zuijdgeest-van Leeuwen, SD, van den Berg, JW, Wattimena, JL et al. (2000) Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism 49, 931–936.
28.Agustsson, T, Ryden, M, Hoffstedt, J et al. (2007) Mechanism of increased lipolysis in cancer cachexia. Cancer Res 67, 5531–5537.
29.Shaw, JH & Wolfe, RR (1987) Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 205, 368–376.
30.Drott, C, Persson, H & Lundholm, K (1989) Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin Physiol 9, 427–439.
31.Thompson, MP, Cooper, ST, Parry, BR et al. (1993) Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1180, 236–242.
32.Laurencikiene, J, Stenson, BM, Arvidsson Nordstrom, E et al. (2008) Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res 68, 9247–9254.
33.Yoshikawa, T, Noguchi, Y, Satoh, S et al. (1997) Insulin resistance and the alterations of glucose transporter-4 in adipose cells from cachectic tumor-bearing rats. JPEN J Parenter Enteral Nutr 21, 347–349.
34.Inadera, H, Nagai, S, Dong, HY et al. (2002) Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int J Cancer 101, 37–45.
35.Bing, C, Taylor, S, Tisdale, MJ et al. (2001) Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 79, 1004–1012.
36.Thompson, MP, Koons, JE, Tan, ET et al. (1981) Modified lipoprotein lipase activities, rates of lipogenesis, and lipolysis as factors leading to lipid depletion in C57BL mice bearing the preputial gland tumor, ESR-586. Cancer Res 41, 3228–3232.
37.Hale, LP, Price, DT, Sanchez, LM et al. (2001) Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 7, 846–853.
38.Rosen, ED (2005) The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids 73, 31–34.
39.Cerami, A, Ikeda, Y, Le Trang, N et al. (1985) Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 11, 173–177.
40.Plomgaard, P, Fischer, CP, Ibfelt, T et al. (2008) Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab 93, 543–549; Epublication 20 November 2007.
41.Yang, JY, Koo, JH, Yoon, HY et al. (2007) Effect of scopoletin on lipoprotein lipase activity in 3T3-L1 adipocytes. Int J Mol Med 20, 527–531.
42.Ryden, M & Arner, P (2007) Tumour necrosis factor-alpha in human adipose tissue – from signalling mechanisms to clinical implications. J Intern Med 262, 431–438.
43.Lopez-Soriano, J, Llovera, M, Carbo, N et al. (1997) Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. Mol Cell Endocrinol 132, 93–99.
44.Sethi, JK, Xu, H, Uysal, KT et al. (2000) Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett 469, 77–82.
45.Ryden, M, Dicker, A, van Harmelen, V et al. (2002) Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 277, 1085–1091.
46.Zhang, HH, Halbleib, M, Ahmad, F et al. (2002) Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929–2935.
47.Hammarstedt, A, Isakson, P, Gustafson, B et al. (2007) Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin. Biochem Biophys Res Commun 357, 700–706.
48.Cawthorn, WP, Heyd, F, Hegyi, K et al. (2007) Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 14, 1361–1373.
49.Hauner, H, Petruschke, T, Russ, M et al. (1995) Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38, 764–771.
50.Masaki, T, Yoshimatsu, H, Chiba, S et al. (1999) Tumor necrosis factor-alpha regulates in vivo expression of the rat UCP family differentially. Biochim Biophys Acta 1436, 585–592.
51.Busquets, S, Carbo, N, Almendro, V et al. (2001) Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia? FEBS Lett 505, 255–258.
52.Kayacan, O, Karnak, D, Beder, S et al. (2006) Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 29, 328–335.
53.Iwase, S, Murakami, T, Saito, Y et al. (2004) Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15, 312–316.
54.Karayiannakis, AJ, Syrigos, KN, Polychronidis, A et al. (2001) Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21, 1355–1358.
55.Fortunati, N, Manti, R, Birocco, N et al. (2007) Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep 18, 1521–1527.
56.Trujillo, ME, Sullivan, S, Harten, I et al. (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89, 5577–5582.
57.Zaki, MH, Nemeth, JA & Trikha, M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111, 592–595.
58.Baltgalvis, KA, Berger, FG, Pena, MM et al. (2008) Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 294, R393–R401.
59.Richey, LM, George, JR, Couch, ME et al. (2007) Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res 13, 6561–6567.
60.Krzystek-Korpacka, M, Matusiewicz, M, Diakowska, D et al. (2007) Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 40, 1353–1360.
61.Kuroda, K, Nakashima, J, Kanao, K et al. (2007) Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69, 113–117.
62.Fain, JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74, 443–477.
63.Bing, C, Brown, M, King, P et al. (2000) Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 60, 2405–2410.
64.Ryden, M, Agustsson, T, Laurencikiene, J et al. (2008) Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia. Cancer 113, 1695–1704.
65.Burgi, W & Schmid, K (1961) Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem 236, 1066–1074.
66.Tada, T, Ohkubo, I, Niwa, M et al. (1991) Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 39, 1221–1226.
67.Sanchez, LM, Chirino, AJ & Bjorkman, P (1999) Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Science 283, 1914–1919.
68.Diez-Itza, I, Sanchez, LM, Allende, MT et al. (1993) Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 29A, 1256–1260.
69.Irmak, S, Tilki, D, Heukeshoven, J et al. (2005) Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 5, 4296–4304.
70.Hassan, MI, Kumar, V, Kashav, T et al. (2007) Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation. J Sep Sci 30, 1979–1988.
71.Todorov, PT, McDevitt, TM, Meyer, DJ et al. (1998) Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 58, 2353–2358.
72.Hirai, K, Hussey, HJ, Barber, MD et al. (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58, 2359–2365.
73.Ueyama, H, Naitoh, H & Ohkubo, I (1994) Structure and expression of rat and mouse mRNAs for Zn-alpha 2-glycoprotein. J Biochem (Tokyo) 116, 677–681.
74.Bing, C, Russell, ST, Beckett, EE et al. (2002) Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br J Cancer 86, 612–618.
75.Russell, ST, Zimmerman, TP, Domin, BA et al. (2004) Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 1636, 59–68.
76.Russell, ST, Hirai, K & Tisdale, MJ (2002) Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86, 424–428.
77.Sanders, PM & Tisdale, MJ (2004) Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. Br J Cancer 90, 1274–1278.
78.Bing, C, Bao, Y, Jenkins, J et al. (2004) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101, 2500–2505.
79.Bao, Y, Bing, C, Hunter, L et al. (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579, 41–47.
80.Mracek, T, Ding, Q, Tzanavari, T et al. (2009) The adipokine zinc-alpha2-glycoprotein is downregulated with fat mass expansion in obesity. Clin Endocrinol (Oxf) (Epublication ahead of print version; doi: 10.1111/j.1365-2265.2009.03658.x).
81.Dahlman, I, Kaaman, M, Olsson, T et al. (2005) A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 90, 5834–5840.
82.Marrades, MP, Martinez, JA & Moreno-Aliaga, MJ (2008) ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem 64, 61–66.
83.Rolli, V, Radosavljevic, M, Astier, V et al. (2007) Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 581, 394–400.
84.Johnen, H, Lin, S, Kuffner, T et al. (2007) Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 13, 1333–1340.
85.Ding, Q, Mracek, T, Gonzalez-Muniesa, P et al. (2009) Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 150, 1688–1696.